Intuitive Surgical Shares Plunge as Da Vinci Procedure Growth Slows Sharply
GLP-1 drugs and insurance uncertainty weigh on demand.
GLP-1 drugs and insurance uncertainty weigh on demand.
Intuitive Surgical beats Q3 earnings expectations with strong da Vinci and Ion system sales, driving shares up 14% and prompting multiple analyst upgrades.